9 big takeaways from the $74 billion Bristol-Celgene deal - STAT

9 big takeaways from the $74 billion Bristol-Celgene deal - STAT


Each month, STAT Plus aims to bring our readers market-moving analysis of the biotech, pharma, and life sciences industries. Our team of veteran reporters — from Sharon Begley to Matthew Herper — help cut through the noise to bring you the most impactful headlines, and analysis of the people, policies, and scientific breakthroughs making waves in the industry.

9 big takeaways from the $74 billion Bristol-Celgene deal

By DAMIAN GARDE @damiangarde, ADAM FEUERSTEIN @adamfeuerstein, and ED SILVERMAN @Pharmalot

JANUARY 3, 2019